<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />
  <meta name="theme-color" content="#090e1a" />
  <title>Regulina-T™ | RGN-T1™ IMMUNOREGULATOR — Investor One-Pager</title>
  <meta name="description" content="Regulina-T™ — the world's first thymus immuno-regenerative platform powered by RGN-T1™ (≥95% purity). Bilingual investor landing page.">
  <!-- Font Awesome (icons) -->
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.0/css/all.min.css" referrerpolicy="no-referrer" />
  <style>
    :root{
      --bg:#090e1a; --ink:#e6f0ff; --sky:#6ab0ff; --indigo:#2e6cf6; --violet:#8b5cf6; --emerald:#21e3b5; --muted:#a7b3c6;
      --section-y:60px; --gap-card:24px; --btn-h:44px; --btn-gap:14px; --mcta-pad:96px;
    }
    *{box-sizing:border-box}
    html,body{height:100%}
    html,body{
      margin:0;padding:0;overflow-x:hidden;
      background:
        radial-gradient(60vw 35vw at 20% -10%, rgba(139,92,246,.18), transparent 60%),
        radial-gradient(55vw 35vw at 95% 10%,  rgba(46,108,246,.18), transparent 60%),
        radial-gradient(70vw 40vw at 30% 105%, rgba(33,227,181,.12), transparent 60%),
        var(--bg);
      background-repeat:no-repeat; background-attachment:scroll;
      color:#fff; font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Inter,Helvetica,Arial,"Apple Color Emoji","Segoe UI Emoji";
    }
    a{color:inherit;text-decoration:none}
    .container{max-width:1100px;margin:0 auto;padding:0 20px}
    .muted{color:#cfd6e6}
    p,ul,ol{margin:0 0 16px; line-height:1.6}
    ul{padding-left:1.1rem}
    .lead{color:#dce6fb;font-size:1.05rem}
    .subtle{color:#9fb2cf;font-size:.95rem}
    .kicker{letter-spacing:.2em;text-transform:uppercase;color:#c7d2e0;font-size:.82rem}
    .title{font-size:clamp(34px,5vw,60px);line-height:1.1;font-weight:700;background:linear-gradient(90deg,#aee2ff,#c7c9ff,#b7ffe8);-webkit-background-clip:text;background-clip:text;color:transparent}
    .h2{font-size:clamp(26px,3.5vw,38px);font-weight:700}
    .grid{display:grid;gap:var(--gap-card)}
    .grid-2{grid-template-columns:repeat(2,minmax(0,1fr))}
    .grid-3{grid-template-columns:repeat(3,minmax(0,1fr))}
    @media (max-width:900px){ .grid-2,.grid-3{grid-template-columns:1fr} }
    .tile{padding:18px;border-radius:16px;border:1px solid rgba(255,255,255,.12);background:linear-gradient(180deg, rgba(255,255,255,.12), rgba(255,255,255,.05));box-shadow:0 10px 30px rgba(0,0,0,.25)}
    .bullet{display:flex;gap:10px;align-items:flex-start}
    .bullet i{margin-top:2px}
    .btn{display:inline-flex;align-items:center;justify-content:center;gap:.5rem;padding:.8rem 1.1rem;border-radius:16px;font-weight:600;min-height:var(--btn-h)}
    .btn-primary{background:linear-gradient(90deg,var(--sky),var(--indigo)); box-shadow:0 0 24px rgba(99,102,241,.35)}
    .btn-ghost{background:rgba(255,255,255,.1);border:1px solid rgba(255,255,255,.15)}
    .btn-row{display:flex;flex-wrap:wrap;gap:12px;margin:var(--btn-gap) 0}
    header{position:sticky;top:0;z-index:5;background:rgba(255,255,255,.05);backdrop-filter:blur(6px);border-bottom:1px solid rgba(255,255,255,.12)}
    nav a{color:#d0daea} nav a:hover{color:#fff}
    .row{display:flex;align-items:center;justify-content:space-between;gap:16px;padding:14px 0}
    .lang{position:fixed;top:60px;right:20px;z-index:10;display:flex;flex-direction:column;gap:4px;padding:4px;border:1px solid rgba(255,255,255,.15);border-radius:12px;background:rgba(255,255,255,.08);backdrop-filter:blur(6px);font-size:.85rem}
    .lang button{border:0;background:transparent;color:#cfe2ff;padding:.28rem .5rem;border-radius:10px;cursor:pointer;line-height:1}
    .lang button.active{background:rgba(255,255,255,.12);color:#fff}
    .hero{padding:var(--section-y) 0}
    .section{padding:var(--section-y) 0}
    .grad-line{height:1px;background:linear-gradient(90deg,transparent,rgba(255,255,255,.25),transparent);margin:0}
    /* USP pills */
    .usp{margin-top:18px}
    .usp-grid{display:grid;gap:12px;grid-template-columns:repeat(3,minmax(0,1fr))}
    @media (max-width:900px){ .usp-grid{grid-template-columns:1fr} }
    .usp-item{position:relative;border-radius:999px;padding:12px 16px;display:flex;align-items:center;gap:12px;background:rgba(255,255,255,.06);box-shadow:0 10px 30px rgba(0,0,0,.25),0 0 22px rgba(106,176,255,.10),0 0 28px rgba(139,92,246,.06);overflow:hidden;opacity:0;transform:translateY(10px)}
    .usp-item::before{content:"";position:absolute;inset:0;padding:1px;border-radius:inherit;background:linear-gradient(90deg,var(--sky),var(--violet));-webkit-mask:linear-gradient(#000 0 0) content-box, linear-gradient(#000 0 0);-webkit-mask-composite:xor;mask-composite:exclude;pointer-events:none}
    .usp-item::after{content:"";position:absolute;inset:-12px;border-radius:inherit;background:radial-gradient(30rem 8rem at 20% 50%, rgba(106,176,255,.12), transparent 60%);filter:blur(16px);z-index:-1}
    .usp-icon{font-size:1.15rem;color:#d6e6ff;transition:transform .25s ease, filter .25s ease}
    .usp-text{font-weight:600;letter-spacing:.2px}
    .usp-item:hover .usp-icon,.usp-item:active .usp-icon{filter:drop-shadow(0 0 8px rgba(106,176,255,.7));transform:translateY(-1px) scale(1.02)}
    .usp-item.in{opacity:1;transform:none;transition:opacity .6s ease, transform .6s ease}
    /* Mobile bottom CTA */
    .m-cta{position:fixed;left:50%;transform:translateX(-50%);bottom:calc(12px + env(safe-area-inset-bottom));padding:0 16px;z-index:10;display:none;width:100%;max-width:1100px}
    @supports (bottom: constant(safe-area-inset-bottom)){ .m-cta{bottom:calc(12px + constant(safe-area-inset-bottom))} }
    .m-cta .bar{display:flex;gap:10px;border-radius:16px;background:rgba(255,255,255,.1);border:1px solid rgba(255,255,255,.15);backdrop-filter:blur(10px);padding:8px;transform:scale(.5);transform-origin:center bottom}
    .m-cta .btn{flex:1;min-height:var(--btn-h)}
    @media (max-width:768px){
      .m-cta{display:block}
      body{padding-bottom:calc(var(--mcta-pad) + env(safe-area-inset-bottom))}
      @supports (padding: constant(safe-area-inset-bottom)){ body{padding-bottom:calc(var(--mcta-pad) + constant(safe-area-inset-bottom))} }
    }
    footer.section{padding:var(--section-y) 0}
    .foot{text-align:center;color:#a8b6cf}
  </style>
</head>
<body>
  <header>
    <div class="container row">
      <div class="muted" style="overflow:hidden;text-overflow:ellipsis;white-space:nowrap;max-width:55vw">
        <i class="fa-solid fa-flask-vial" style="margin-right:.5rem;color:#cfd6e6"></i>
        <strong>Regulina-T™ | RGN-T1™ IMMUNOREGULATOR</strong>
      </div>
      <nav class="muted" style="display:flex;gap:18px;font-size:.95rem">
        <a href="#tech" data-i18n="nav.tech">Tech</a>
        <a href="#license" data-i18n="nav.license">License</a>
        <a href="#market" data-i18n="nav.market">Market</a>
        <a href="#escrow" data-i18n="nav.escrow">Escrow</a>
        <a href="#contact" data-i18n="nav.contact">Contact</a>
      </nav>
      <div class="lang"><button id="btnRU">RU</button><button id="btnEN" class="active">EN</button></div>
    </div>
  </header>

  <main class="container">
    <!-- HERO -->
    <section class="hero">
      <p class="kicker" data-i18n="hero.kicker">The world's first thymus immuno-regenerative platform</p>
      <h1 class="title">Regulina-T™ <span class="nowrap">IMMUNOREGULATOR</span></h1>
      <p class="lead" data-i18n="hero.lead">Powered by the gene-engineered protein <b>RGN-T1™</b> (≥95% purity). A breakthrough technology designed to restore thymus function and re-balance the immune system.*</p>

      <!-- USP pills -->
      <div class="usp">
        <div class="usp-grid">
          <div class="usp-item reveal"><i class="fa-solid fa-dna usp-icon" aria-hidden="true"></i><div class="usp-text" data-i18n="usp.1">Thymus Immunoregeneration</div></div>
          <div class="usp-item reveal"><i class="fa-solid fa-flask-vial usp-icon" aria-hidden="true"></i><div class="usp-text" data-i18n="usp.2">RGN-T1™ ≥95% purity</div></div>
          <div class="usp-item reveal"><i class="fa-solid fa-file-shield usp-icon" aria-hidden="true"></i><div class="usp-text" data-i18n="usp.3">Escrow-ready IP package</div></div>
        </div>
      </div>
    </section>

    <div class="grad-line"></div>

    <!-- TECHNOLOGY -->
    <section id="tech" class="section anchor">
      <h2 class="h2" data-i18n="tech.h2">Technology Foundation</h2>
      <p class="lead" data-i18n="tech.desc">The platform targets age-related RGN decline to restore immune homeostasis.</p>

      <div class="grid grid-2">
        <div class="tile">
          <div class="bullet">
            <i class="fa-solid fa-vial"></i>
            <div>
              <b data-i18n="tech.t1.title">Recombinant RGN-T1™ protein</b>
              <div class="subtle" data-i18n="tech.t1.text">Lab-produced, reproducible, ≥95% purity.</div>
            </div>
          </div>
        </div>
        <div class="tile">
          <div class="bullet">
            <i class="fa-solid fa-dna"></i>
            <div>
              <b data-i18n="tech.t2.title">Molecular-level know-how</b>
              <div class="subtle" data-i18n="tech.t2.text">Gene, vector, host strain, expression & purification.</div>
            </div>
          </div>
        </div>
        <div class="tile">
          <div class="bullet">
            <i class="fa-solid fa-syringe"></i>
            <div>
              <b data-i18n="tech.t3.title">Injectable form (IV/IM)</b>
              <div class="subtle" data-i18n="tech.t3.text">Standard dosing scheme; storage and stability.</div>
            </div>
          </div>
        </div>
        <div class="tile">
          <div class="bullet">
            <i class="fa-solid fa-lock"></i>
            <div>
              <b data-i18n="tech.t4.title">Escrow transfer</b>
              <div class="subtle" data-i18n="tech.t4.text">Materials and samples delivered via a protected escrow structure.</div>
            </div>
          </div>
        </div>
      </div>

      <p class="subtle" data-i18n="tech.note">* The technology is subject to clinical validation. Commercialization includes preclinical work and Phases I–III per regulatory requirements.</p>
    </section>

    <div class="grad-line"></div>

    <!-- LICENSE -->
    <section id="license" class="section anchor">
      <h2 class="h2" data-i18n="license.h2">Licensing Model</h2>
      <div class="grid grid-3">
        <div class="tile"><div class="subtle" data-i18n="license.i1"><b>Global exclusive license</b> for 20 years.</div></div>
        <div class="tile"><div class="subtle" data-i18n="license.i2">Licensee obligations: preclinical, in vitro/in vivo and clinical Phases I–III.</div></div>
        <div class="tile"><div class="subtle" data-i18n="license.i3">Authorship & IP retained by TK; samples & full package via escrow.</div></div>
      </div>
    </section>

    <div class="grad-line"></div>

    <!-- MARKET / PRICING -->
    <section id="market" class="section anchor">
      <h2 class="h2" data-i18n="market.h2">Market Potential</h2>
      <div class="grid grid-3">
        <div class="tile"><div class="subtle" data-i18n="market.m1.label">Potential patients</div><div style="font-size:1.5rem;font-weight:700;margin-top:8px">~2.5B</div></div>
        <div class="tile"><div class="subtle" data-i18n="market.m2.label">Target patients / year</div><div style="font-size:1.5rem;font-weight:700;margin-top:8px">~50M</div></div>
        <div class="tile"><div class="subtle" data-i18n="market.m3.label">Expected revenue</div><div style="font-size:1.5rem;font-weight:700;margin-top:8px">&gt;$50B/yr</div></div>
      </div>

      <div class="grid grid-2" style="margin-top:var(--gap-card)">
        <div class="tile">
          <div class="h2" style="font-size:1.05rem;margin-bottom:.8rem" data-i18n="pricing.h2">Scientific & ethical pricing</div>
          <ul class="subtle">
            <li data-i18n="pricing.b1">~9 injections/year (range 4–12).</li>
            <li data-i18n="pricing.b2">200 µg per dose — minimally sufficient.</li>
            <li data-i18n="pricing.b3">Average therapy cost: ~$900/year (max ~$1,600).</li>
            <li data-i18n="pricing.b4">Mass accessibility with sustainable unit economics.</li>
          </ul>
        </div>
        <div class="tile">
          <p class="subtle" data-i18n="pricing.note">Accessible pricing at scale with a transparent royalty model enables long-term revenues and strong social impact.</p>
          <div class="subtle" style="margin-top:8px"><i class="fa-solid fa-shield-heart" style="margin-right:.5rem"></i><span data-i18n="pricing.win">Win-Win for patients and licensee.</span></div>
        </div>
      </div>
    </section>

    <div class="grad-line"></div>

    <!-- ESCROW -->
    <section id="escrow" class="section anchor">
      <h2 class="h2" data-i18n="escrow.h2">Escrow Package Contents</h2>
      <div class="grid grid-3">
        <div class="tile"><div class="subtle"><i class="fa-solid fa-file-lines" style="margin-right:.5rem"></i><span data-i18n="escrow.i1">Patent and IP filings</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-solid fa-dna" style="margin-right:.5rem"></i><span data-i18n="escrow.i2">Molecular know-how (gene, vector, host, expression)</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-solid fa-flask-vial" style="margin-right:.5rem"></i><span data-i18n="escrow.i3">Final drug formula (with codes)</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-solid fa-droplet" style="margin-right:.5rem"></i><span data-i18n="escrow.i4">Stabilizing buffer</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-solid fa-syringe" style="margin-right:.5rem"></i><span data-i18n="escrow.i5">Injectable form (IV/IM), baseline dosing</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-regular fa-snowflake" style="margin-right:.5rem"></i><span data-i18n="escrow.i6">Storage conditions and shelf-life</span></div></div>
        <div class="tile"><div class="subtle"><i class="fa-solid fa-filter-circle-dollar" style="margin-right:.5rem"></i><span data-i18n="escrow.i7">Complete purification scheme to ≥95%</span></div></div>
      </div>
      <p class="subtle" data-i18n="escrow.note">Materials and samples are delivered via a secure escrow structure.</p>
    </section>

    <div class="grad-line"></div>

    <!-- CONTACT -->
    <section id="contact" class="section anchor">
      <h2 class="h2" data-i18n="contact.h2">Contact the Author & IP Owner</h2>

      <div class="grid grid-2">
        <div class="tile">
          <a class="btn btn-primary" href="mailto:anaklia20@gmail.com?subject=Regulina-T%20NDA%20%2F%20Investor%20Deck">
            <i class="fa-solid fa-envelope"></i>
            <span style="margin-left:.5rem" data-i18n="contact.btn_ndadeck">Request NDA / Investor Deck</span>
          </a>

          <div class="btn-row">
            <a class="btn btn-ghost" href="https://wa.me/447440448317" target="_blank" rel="noopener">
              <i class="fa-brands fa-whatsapp"></i>
              <span style="margin-left:.5rem" data-i18n="contact.btn_whatsapp">Open WhatsApp</span>
            </a>
            <a class="btn btn-ghost" href="mailto:anaklia20@gmail.com">
              <i class="fa-solid fa-envelope"></i>
              <span style="margin-left:.5rem" data-i18n="contact.btn_email">Send Email</span>
            </a>
          </div>

          <div class="subtle">
            <div><b data-i18n="contact.wa_label">WhatsApp:</b> +44 7440 448317</div>
            <div><b data-i18n="contact.email_label">Email:</b> anaklia20@gmail.com</div>
          </div>
        </div>

        <div class="tile">
          <div class="subtle">
            <i class="fa-regular fa-file-lines" style="margin-right:.5rem"></i>
            <span data-i18n="contact.req">Available on request: regulatory requirements and clinical roadmap.</span>
          </div>
        </div>
      </div>
    </section>

    <footer class="section">
      <div class="foot" data-i18n="footer.copy">© TK — Author & owner of the Regulina-T™ platform</div>
    </footer>
  </main>

  <!-- Mobile bottom CTA -->
  <div class="m-cta" aria-hidden="false">
    <div class="container">
      <div class="bar">
        <a class="btn btn-primary" href="https://wa.me/447440448317" target="_blank" rel="noopener">
          <i class="fa-brands fa-whatsapp"></i> <span style="margin-left:.5rem" data-i18n="cta.whatsapp">WhatsApp</span>
        </a>
        <a class="btn btn-ghost" href="mailto:anaklia20@gmail.com?subject=Regulina-T%20Investor%20Materials%20Request">
          <i class="fa-regular fa-file-lines"></i> <span style="margin-left:.5rem" data-i18n="cta.materials">Materials</span>
        </a>
      </div>
    </div>
  </div>

  <script>
    // --- i18n dictionary (all texts centralized) ---
    const i18n = {
      en: {
        nav: { tech: "Tech", license: "License", market: "Market", escrow: "Escrow", contact: "Contact" },
        hero: {
          kicker: "The world's first thymus immuno-regenerative platform",
          lead: "Powered by the gene-engineered protein <b>RGN-T1™</b> (≥95% purity). A breakthrough technology designed to restore thymus function and re-balance the immune system.*"
        },
        usp: {
          1: "Thymus Immunoregeneration",
          2: "RGN-T1™ ≥95% purity",
          3: "Escrow-ready IP package"
        },
        tech: {
          h2: "Technology Foundation",
          desc: "The platform targets age-related RGN decline to restore immune homeostasis.",
          t1: { title: "Recombinant RGN-T1™ protein", text: "Lab-produced, reproducible, ≥95% purity." },
          t2: { title: "Molecular-level know-how", text: "Gene, vector, host strain, expression & purification." },
          t3: { title: "Injectable form (IV/IM)", text: "Standard dosing scheme; storage and stability." },
          t4: { title: "Escrow transfer", text: "Materials and samples delivered via a protected escrow structure." },
          note: "* The technology is subject to clinical validation. Commercialization includes preclinical work and Phases I–III per regulatory requirements."
        },
        license: {
          h2: "Licensing Model",
          i1: "<b>Global exclusive license</b> for 20 years.",
          i2: "Licensee obligations: preclinical, in vitro/in vivo and clinical Phases I–III.",
          i3: "Authorship & IP retained by TK; samples & full package via escrow."
        },
        market: {
          h2: "Market Potential",
          m1: { label: "Potential patients" },
          m2: { label: "Target patients / year" },
          m3: { label: "Expected revenue" }
        },
        pricing: {
          h2: "Scientific & ethical pricing",
          b1: "~9 injections/year (range 4–12).",
          b2: "200 µg per dose — minimally sufficient.",
          b3: "Average therapy cost: ~$900/year (max ~$1,600).",
          b4: "Mass accessibility with sustainable unit economics.",
          note: "Accessible pricing at scale with a transparent royalty model enables long-term revenues and strong social impact.",
          win: "Win-Win for patients and licensee."
        },
        escrow: {
          h2: "Escrow Package Contents",
          i1: "Patent and IP filings",
          i2: "Molecular know-how (gene, vector, host, expression)",
          i3: "Final drug formula (with codes)",
          i4: "Stabilizing buffer",
          i5: "Injectable form (IV/IM), baseline dosing",
          i6: "Storage conditions and shelf-life",
          i7: "Complete purification scheme to ≥95%",
          note: "Materials and samples are delivered via a secure escrow structure."
        },
        contact: {
          h2: "Contact the Author & IP Owner",
          btn_ndadeck: "Request NDA / Investor Deck",
          btn_whatsapp: "Open WhatsApp",
          btn_email: "Send Email",
          wa_label: "WhatsApp:",
          email_label: "Email:",
          req: "Available on request: regulatory requirements and clinical roadmap."
        },
        footer: { copy: "© TK — Author & owner of the Regulina-T™ platform" },
        cta: { whatsapp: "WhatsApp", materials: "Materials" }
      },
      ru: {
        nav: { tech: "Технологии", license: "Лицензия", market: "Рынок", escrow: "Эскроу", contact: "Контакты" },
        hero: {
          kicker: "Первая в мире иммунорегенеративная платформа тимуса",
          lead: "Основана на генно-инженерно полученном белке <b>RGN-T1™</b> (чистота ≥95%). Новая технология, способная восстанавливать функцию тимуса и регулировать иммунную систему.*"
        },
        usp: {
          1: "Иммунорегенерация тимуса",
          2: "RGN-T1™ ≥95% чистота",
          3: "Эскроу-готовый пакет ИС"
        },
        tech: {
          h2: "Технологическая основа",
          desc: "Цель платформы — восполнить снижение уровня RGN с возрастом и восстановить иммунный гомеостаз.",
          t1: { title: "Рекомбинантный белок RGN-T1™", text: "Лабораторно получаемый, воспроизводимый, чистота ≥95%." },
          t2: { title: "Know-how на молекулярном уровне", text: "Ген, вектор, хост-штамм, экспрессия и очистка." },
          t3: { title: "Инъекционная форма (IV/IM)", text: "Стандартная схема дозирования; хранение и стабильность." },
          t4: { title: "Передача через эскроу", text: "Материалы и образцы предоставляются через защищённую эскроу-структуру." },
          note: "* Технология подлежит клинической валидации. Коммерциализация включает доклинику и фазы I–III по требованиям регуляторов."
        },
        license: {
          h2: "Лицензионная модель",
          i1: "<b>Глобальная эксклюзивная лицензия</b> сроком на 20 лет.",
          i2: "Обязанности лицензиата: доклиника, in vitro/in vivo и клинические фазы I–III.",
          i3: "Авторство и права ИС сохраняются за TK; образцы и полный пакет — через эскроу."
        },
        market: {
          h2: "Потенциал рынка",
          m1: { label: "Потенциальные пациенты" },
          m2: { label: "Целевая аудитория / год" },
          m3: { label: "Ожидаемая выручка" }
        },
        pricing: {
          h2: "Научные и этические основы ценообразования",
          b1: "В среднем 9 инъекций/год (диапазон 4–12).",
          b2: "200 мкг белка на дозу — минимально достаточный объём.",
          b3: "Средняя стоимость терапии: ~$900/год (макс. ~$1 600/год).",
          b4: "Массовая доступность при устойчивой экономике проекта.",
          note: "Доступная цена при масштабировании и прозрачная модель роялти обеспечивают долгосрочную выручку и высокий социальный эффект.",
          win: "Win-Win: пациент и лицензиат."
        },
        escrow: {
          h2: "Состав эскроу-пакета",
          i1: "Патентные и ИС-заявки",
          i2: "Генно-инженерное know-how (ген, вектор, хост, экспрессия)",
          i3: "Окончательная формула препарата (с кодами)",
          i4: "Стабилизирующий буфер",
          i5: "Инъекционная форма (IV/IM), базовая схема дозирования",
          i6: "Условия хранения и срок годности",
          i7: "Полная схема очистки до ≥95%",
          note: "Материалы и образцы поставляются через безопасную эскроу-структуру."
        },
        contact: {
          h2: "Связаться с автором и правообладателем",
          btn_ndadeck: "Запросить NDA / Investor Deck",
          btn_whatsapp: "Открыть WhatsApp",
          btn_email: "Написать письмо",
          wa_label: "WhatsApp:",
          email_label: "Email:",
          req: "По запросу: требования регуляторов и дорожная карта клинических фаз."
        },
        footer: { copy: "© TK — Автор и владелец платформы Regulina-T™" },
        cta: { whatsapp: "WhatsApp", materials: "Материалы" }
      }
    };

    // --- i18n engine ---
    const btnRU = document.getElementById('btnRU');
    const btnEN = document.getElementById('btnEN');

    function applyTranslations(lang){
      const dict = i18n[lang] || i18n.en;
      document.documentElement.lang = lang === 'ru' ? 'ru' : 'en';
      // set text/HTML for all [data-i18n]
      document.querySelectorAll('[data-i18n]').forEach(el=>{
        const key = el.getAttribute('data-i18n');
        const value = key.split('.').reduce((acc,k)=>acc && acc[k], dict);
        if (value != null){
          // use innerHTML to support <b> where present in strings
          el.innerHTML = value;
        }
      });
      // toggle active state
      btnRU.classList.toggle('active', lang==='ru');
      btnEN.classList.toggle('active', lang==='en');
      localStorage.setItem('lang', lang);
    }

    function setLang(lang){ applyTranslations(lang); }

    btnRU.addEventListener('click', ()=>setLang('ru'));
    btnEN.addEventListener('click', ()=>setLang('en'));

    // Default language: EN on first visit, then user choice from localStorage
    const stored = localStorage.getItem('lang');
    setLang(stored || 'en');

    // USP reveal animation
    const io = new IntersectionObserver((entries)=>{
      entries.forEach(e=>{ if(e.isIntersecting){ e.target.classList.add('in'); io.unobserve(e.target);} });
    }, {threshold:0.2});
    document.querySelectorAll('.usp-item').forEach(el=>io.observe(el));
  </script>
</body>
</html>
